Hello,
As a researcher working primarily in the AAV field, I am well aware of the issue with neutralizing antibodies against AAV that prevent re-administration of vector. I have never heard anyone in the lentivirus field talking about this and I am wondering if the same limitations apply to this vector system. My questions are:
1) do hosts (animals, people) make antibodies or T cell responses against lentiviral envelope proteins? If so, do these antibodies limit the efficacy of re-administrated vector?
2) can anyone give me a reference that shows repeated i.v. administration of lentiviruses is safe and effective?
Thanks,
John
Jonathan,
LV is a better candidate for repeat injections than AAV, however I have never seen again reference which clearly shows the safety of repeat administrations of LV.
In my R&D department, we develope new lentiviral vectors which are deficient for reverse transcription, the RNA genomes are taken in charge as a mRNA by the transduced cells. Consequently the transduction is very safe but very transient. We already done repeat transductions with mice and for the moment we didn't see any adverse effect but we have to investigate again to give a clear answer about that.
Some ref :
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2573216/
http://www.google.com/patents/US20100076061
https://clinicaltrials.gov/ct2/show/NCT00131560
Nicolas
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Biology
- Molecular Methods
- Cloning